NASDAQ$COO

The Cooper Companies Inc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

CooperCompanies reported Q4 2022 results with revenue up 12% year-over-year and EPS down 40%.

CooperCompanies announced its Q4 and full year 2022 results, with Q4 revenue increasing by 12% to $848.1 million. GAAP diluted EPS for the quarter was $1.32, a decrease of 40% compared to the previous year. The company closed the fiscal year with record annual revenue driven by gains in contact lenses and fertility.

  • Fourth quarter revenue increased 12% year-over-year to $848.1 million.
  • Fourth quarter GAAP diluted earnings per share (EPS) of $1.32, down 40% from last year's fourth quarter.
  • Fourth quarter Non-GAAP diluted EPS of $2.75, down 16% from last year's fourth quarter.
  • Free cash flow of $35.8 million.

Headline financials

Total Revenue

$848M

Previous: $759M+11.7%
EPS (adj)

$0.69

Previous: $0.82-15.9%
GAAP Gross Margin

63.0%

Previous: 66.0%-4.5%
GAAP Operating Margin

12.0%

Previous: 17.0%-29.4%
Capital Expenditures

$94.9M

Previous: $65M+46.0%
Free Cash Flow

$35.8M

Previous: $110M-67.3%
Net Income

$65.6M

Previous: $110M-40.5%
Operating Income

$104M

Previous: $129M-19.5%
Gross Profit

$537M

Previous: $502M+6.9%
Cash & Equivalents

$138M

Previous: $95.9M+44.1%
Total Assets

$11.5B

Previous: $9.61B+19.6%
Stock-Based Comp

$54.2M

Previous: $43.8M+23.7%

Revenue & EPS history

Cooper · Revenue · Quarterly

$848M

Q4 2022+11.7%vs Q4 2021
Beat estimate in 9 of 16 quarters(56%)
ActualEstimate

Revenue by segment

Cooper · $286M total across 2 segments · Q4 2022

  • Office and Surgical
    $178M+57.8%
  • Fertility
    $109M+33.0%

Forward guidance

The Company initiated its fiscal year 2023 guidance. Fiscal 2023 total revenue of $3,455 - $3,515 million (organic growth of 6% to 8%). Fiscal 2023 non-GAAP diluted earnings per share of $12.30 - $12.60.

Tailwinds

  • Fiscal 2023 total revenue of $3,455 - $3,515 million (organic growth of 6% to 8%)
  • CVI revenue of $2,325 - $2,365 million (organic growth of 7% to 9%)
  • CSI revenue of $1,130 - $1,150 million (organic growth of 4% to 6%)
  • Fiscal 2023 non-GAAP diluted earnings per share of $12.30 - $12.60
  • Focus on delivering market share gains and long-term shareholder value.

Headwinds

  • Fiscal year 2023 guidance does not include the Cook Medical Reproductive Health acquisition announced on February 7, 2022, as the transaction is pending regulatory approval.
  • Non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets, and other exceptional or unusual income or gains and charges or expenses including acquisition, integration and manufacturing related costs which we may incur as part of our continuing operations.
  • The Company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses
  • Adverse changes in the global or regional general business, political and economic conditions.
  • The effects of the COVID-19 pandemic and related economic disruptions and new governmental regulations on our business, results of operations, cash flow and financial condition

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

+0.6%

Avg return

Earnings day

-0.3%

Avg return

5 days after

-0.1%

Avg return

30 days after

52%

36 / 69 earnings

Positive

+12.1%

Q3 2024

Best reaction

-12.8%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026+10.3%+9.7%
Q1 2026-4.6%-8.0%-12.5%
Q4 2025-4.3%+4.8%+5.3%
Q3 2025-12.8%-11.8%-8.9%
Q2 2025+0.0%-0.3%+3.6%
Q1 2025-6.6%-13.1%-18.9%
Q4 2024-6.0%-5.6%-12.6%
Q3 2024+12.1%+12.1%+16.4%
Q2 2024+3.5%+3.8%-4.2%
Q1 2024+8.1%+7.3%+7.4%
Q4 2023-2.2%-0.7%+6.8%
Q3 2023-2.1%-3.5%-15.9%
Q2 2023-4.0%-5.1%+3.2%
Q1 2023+8.7%+3.9%+15.4%
Q4 2022-1.6%+4.8%+9.7%
Q3 2022+4.1%+2.5%-8.5%
Q2 2022-0.3%+1.3%-7.2%
Q1 2022+2.1%-8.5%+3.1%
Q4 2021+4.8%+8.7%+12.2%
Q3 2021+1.1%-0.7%-7.6%
Q2 2021-0.7%-3.2%+6.0%
Q1 2021+1.8%+0.3%+1.1%
Q4 2020+3.3%+3.3%+8.6%
Q3 2020+2.0%+0.3%+5.7%
Q2 2020-0.2%-5.0%-9.1%
Q1 2020-1.3%-0.9%-17.3%
Q4 2019-1.6%-2.4%+3.3%
Q3 2019-3.5%-6.7%-8.3%
Q2 2019+4.5%+9.0%+18.2%
Q1 2019-1.8%+0.1%+1.0%
Q4 2018-11.6%-7.3%-10.4%
Q3 2018-3.7%-3.4%+4.3%
Q2 2018+1.4%-0.4%+6.0%
Q1 2018+2.1%-3.8%-11.5%
Q4 2017-3.2%-1.9%-1.5%
Q3 2017-4.0%-2.5%-3.7%
Q2 2017+8.9%+10.5%+9.4%
Q1 2017-3.1%-3.6%-0.4%
Q4 2016+1.3%+4.1%+5.2%
Q3 2016+0.0%+1.3%-3.6%
Q2 2016-0.1%-0.4%+7.1%
Q1 2016+6.4%
Q4 2015-12.8%
Q3 2015-7.1%
Q2 2015-5.1%
Q1 2015+9.7%
Q4 2014-4.4%
Q3 2014+0.7%
Q2 2014+1.7%
Q1 2014+4.3%
Q4 2013-4.6%
Q3 2013-1.8%
Q2 2013+8.1%
Q1 2013+2.5%
Q4 2012+1.0%
Q3 2012+10.3%
Q2 2012-4.1%
Q1 2012+2.8%
Q4 2008+2.8%
Q4 2011+2.8%
Q3 2011-1.8%
Q2 2011+1.4%
Q2 2010+1.4%
Q1 2010+8.9%
Q1 2011+1.0%
Q4 2010-1.5%
Q3 2010+5.8%
Q4 2009+5.8%
Q3 2009+5.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro